FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Paul O'Connor

Research Profile

Disorders

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Ludwig Kappos; Paul W O'Connor; Amy Pace; Christopher H Polman; Patrick Vermersch; Heinz Wiendl; Annie Zhang; Christophe Hotermans
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Paul W O'Connor
Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
Bianca Weinstock-Guttman; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Frances Lynn; Paul W O'Connor; J Theodore Phillips; Chris Polman; William H Stuart; Christophe Hotermans
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Paul O'Connor (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ludwig Kappos; Paul W O'Connor; Amy Pace; Christopher H Polman; Patrick Vermersch; Heinz Wiendl; Annie Zhang; Christophe Hotermans
Clinical effects of natalizumab on multiple sclerosis appear early in treatment course.
Journal of neurology 2013;260(5):1388-95.
2012: Paul W O'Connor
Natalizumab risk stratification: role of a two- step anti-JCV antibody assay.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2012;39(5):670-5.
2012: Bianca Weinstock-Guttman; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Frances Lynn; Paul W O'Connor; J Theodore Phillips; Chris Polman; William H Stuart; Christophe Hotermans
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS.
Journal of neurology 2012;259(5):898-905.
2012: Jodie M Burton; Marika Hohol; Paul W O'Connor; Joseph Beyene
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Cochrane database of systematic reviews (Online) 2012;12():CD006921.
2011: Ludwig Kappos; David Bates; Michel Clanet; David B Clifford; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Ralf Gold; Nikolaos Grigoriadis; Hans-Peter Hartung; Stephen Hauser; Eva Havrdová; Jan Hillert; Hans H Hirsch; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Eugene O Major; Ariel Miller; Paul W O'Connor; Carlo Pozzilli; Ernst W Radü; Mads Ravnborg; Takahiko Saida; Christian Sindic; Per Soelberg Sørensen; Karl Vass; Howard L Weiner; John King
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.
Lancet neurology 2011;10(8):745-58.
2011: J Theodore Phillips; Chris H Polman; Ernie Willoughby; Paul W O'Connor; Amy Pace; William Aschenbach; Gavin Giovannoni; Robert Hyde; Fred D Lublin; Frederick E Munschauer
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(8):970-9.
2011: Paul W O'Connor; A Goodman; Ludwig Kappos; Fred D Lublin; D H Miller; C Polman; R A Rudick; W Aschenbach; N Lucas
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis.
Neurology 2011;76(22):1858-65.
2011: Kristen M Krysko; Paul W O'Connor
The toronto observational study of natalizumab in multiple sclerosis.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2011;38(3):422-8.
2010: Richard A Rudick; Paul W O'Connor; Chris H Polman; AD Goodman; Soma S Ray; Nancy M Griffith; Stephanie A Jurgensen; Leonid Gorelik; Fiona Forrestal; Alfred W Sandrock; Susan E Goelz
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Annals of neurology 2010;68(3):304-10.
2010: Dalia L Rotstein; Muhammad Mamdani; Paul W O'Connor
Increasing use of disease modifying drugs for MS in Canada.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2010;37(3):383-8.
2010: Paul W O'Connor
Use of natalizumab in multiple sclerosis patients.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2010;37(1):98-104.
2009: Jodie M Burton; Paul W O'Connor; Marika Hohol; Joseph Beyene
Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
Cochrane database of systematic reviews (Online) 2009;(3):CD006921.
2007: Peter A Calabresi; Gavin Giovannoni; Christian Confavreux; Steven L Galetta; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Fred D Lublin; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.
Neurology 2007;69(14):1391-403.
2007: Richard A Rudick; Deborah Miller; Steve Hass; Michael Hutchinson; Peter A Calabresi; Christian Confavreux; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Health-related quality of life in multiple sclerosis: effects of natalizumab.
Annals of neurology 2007;62(4):335-46.
2007: JT Chen; T Kuhlmann; G H Jansen; D Louis Collins; Harold L Atkins; Mark S Freedman; Paul W O'Connor; Douglas L Arnold
Voxel-based analysis of the evolution of magnetization transfer ratio to quantify remyelination and demyelination with histopathological validation in a multiple sclerosis lesion.
NeuroImage 2007;36(4):1152-8.
2007: Ludwig Kappos; David Bates; Hans-Peter Hartung; Eva Havrdova; David Miller; Chris H Polman; Mads Ravnborg; Stephen L Hauser; Richard A Rudick; Howard L Weiner; Paul W O'Connor; John King; Ernst-Wilhelm Radue; Tarek A Yousry; Eugene O Major; David B Clifford
Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring.
Lancet neurology 2007;6(5):431-41.
2007: David H Miller; Derek Soon; Kryshani T M Fernando; David G MacManus; Gareth Barker; Tarek A Yousry; Elizabeth Fisher; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ludwig Kappos; Michael Hutchinson; Eva Havrdova; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Richard A Rudick; Frances Lynn; Michael A Panzara; Alfred W Sandrock
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.
Neurology 2007;68(17):1390-401.
2007: Laura J Balcer; Steven L Galetta; Peter A Calabresi; Christian Confavreux; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; David H Miller; Paul W O'Connor; J Theodore Phillips; Chris H Polman; Ernst-Wilhelm Radue; Richard A Rudick; William H Stuart; Andrzej Wajgt; Bianca Weinstock-Guttman; Daniel R Wynn; Frances Lynn; Michael A Panzara
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.
Neurology 2007;68(16):1299-304.
2006: J Theodore Phillips; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; Chris H Polman; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Frances Lynn; Michael A Panzara; Alfred W Sandrock
Infusion-related hypersensitivity reactions during natalizumab treatment.
Neurology 2006;67(9):1717-8.
2006: Paul W O'Connor; D Li; Mark S Freedman; A Bar-Or; G P A Rice; Christian Confavreux; Donald W Paty; J A Stewart; Richard D Scheyer
A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
Neurology 2006;66(6):894-900.
2006: Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor; Gordon T Plant; G P A Rice; David H Miller
Ventricular enlargement in MS: one-year change at various stages of disease.
Neurology 2006;66(5):693-8.
2006: Chris H Polman; Paul W O'Connor; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; David H Miller; J Theodore Phillips; Fred D Lublin; Gavin Giovannoni; Andrzej Wajgt; Martin Toal; Frances Lynn; Michael A Panzara; Alfred W Sandrock
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
The New England journal of medicine 2006;354(9):899-910.
2005: Chris H Polman; Stephen C Reingold; Gilles Edan; Massimo Filippi; Hans-Peter Hartung; Ludwig Kappos; Fred D Lublin; Luanne M Metz; Henry McFarland; Paul W O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Brian G Weinshenker; Jerry Wolinsky
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".
Annals of neurology 2005;58(6):840-6.
2005: Lorraine V Kalia; Paul W O'Connor
Severity of chronic pain and its relationship to quality of life in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2005;11(3):322-7.
2005: Melanie R Ursell; Paul W O'Connor
Natalizumab and other monoclonal antibodies.
Neurologic clinics 2005;23(1):233-46, viii.
2004: Paul W O'Connor; A Goodman; Allison J Willmer-Hulme; Michele A Libonati; Luanne M Metz; R S Murray; William A Sheremata; Timothy Vollmer; L A Stone
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects.
Neurology 2004;62(11):2038-43.
2003: Ravi Retnakaran; Marie E Faughnan; Raymond P Chan; Robyn A Pugash; Paul W O'Connor; Chi-Ming Chow
Pulmonary arteriovenous malformation: a rare, treatable cause of stroke in young adults.
International journal of clinical practice 2003;57(8):731-3.
2003: David H Miller; OA Khan; William A Sheremata; Lance D Blumhardt; G P A Rice; Michele A Libonati; Allison J Willmer-Hulme; Catherine M Dalton; Katherine A Miszkiel; Paul W O'Connor
A controlled trial of natalizumab for relapsing multiple sclerosis.
The New England journal of medicine 2003;348(1):15-23.
2001: Shawn Winer; Igor Astsaturov; Roy Cheung; Lakshman Gunaratnam; Violetta Kubiak; Miguel A Cortez; Mario A Moscarello; Paul W O'Connor; Colin McKerlie; Dorothy J Becker; H-Michael Dosch
Type I diabetes and multiple sclerosis patients target islet plus central nervous system autoantigens; nonimmunized nonobese diabetic mice can develop autoimmune encephalitis.
Journal of immunology (Baltimore, Md. : 1950) 2001;166(4):2831-41.